Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Crosses Below 200 Day Moving Average - Time to Sell?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.24 and traded as low as $2.10. Oramed Pharmaceuticals shares last traded at $2.12, with a volume of 38,553 shares changing hands.

Analysts Set New Price Targets

Separately, Wall Street Zen cut shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th.

Oramed Pharmaceuticals Price Performance

The firm's 50-day moving average price is $2.17 and its two-hundred day moving average price is $2.24.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last posted its earnings results on Thursday, May 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.16). The company had revenue of $2.00 million for the quarter. As a group, research analysts expect that Oramed Pharmaceuticals Inc. will post -0.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC increased its stake in Oramed Pharmaceuticals by 36.2% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 18,799 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 5,000 shares in the last quarter. N.E.W. Advisory Services LLC increased its stake in Oramed Pharmaceuticals by 52.9% during the 1st quarter. N.E.W. Advisory Services LLC now owns 18,900 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 6,540 shares in the last quarter. Jane Street Group LLC increased its stake in Oramed Pharmaceuticals by 35.3% during the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock valued at $144,000 after purchasing an additional 17,510 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Oramed Pharmaceuticals by 143.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 70,190 shares in the last quarter. Finally, Peapod Lane Capital LLC increased its stake in Oramed Pharmaceuticals by 11.0% during the 1st quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock valued at $540,000 after purchasing an additional 24,985 shares in the last quarter. Institutional investors and hedge funds own 12.73% of the company's stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.